MicroRNA miR-4709-3p targets Large Tumor Suppressor Kinase 2 (LATS2) and induces obstructive renal fibrosis through Hippo signaling

References

• Humphreys BDJAROP. Mechanisms of renal fibrosis.  Annual review of physiology. 2018;80:309–326.
   Google Scholar
• Arai H, Yanagita M. Janus-faced: molecular mechanisms and versatile nature of renal fibrosis. ResearchGate. 2020;1(7):697–704.
   Google Scholar
• Kawanami D, Matoba K, Utsunomiya K. Signaling pathways in diabetic nephropathy. Histol Histopathol. 2016;31(10):1059–1067.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lv C, Wu C, et al. Suppressor of cytokine signaling (SOCS) 2 attenuates renal lesions in rats with diabetic nephropathy. Acta Histochem. 2014;116(5):981–988.
   PubMed Web of Science ®Google Scholar
• Sun YBY, Qu X, Caruana G, et al. The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. ResearchGate. 2016;92(3):102–107.
   Google Scholar
• Tian J, Xiao Z, Wei J, et al. NCTD prevents renal interstitial fibrosis via targeting Sp1/lncRNA Gm26669 axis. Int J Biol Sci. 2021;17(12):3118–3132.
   PubMed Web of Science ®Google Scholar
• Fioretto P, Zambon A, Rossato M, et al. SGLT2 Inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Supplement 2):S165–S171.
   PubMedGoogle Scholar
• Shabaka A, Cases-Corona C, Fernandez-Juarez G. Therapeutic insights in chronic kidney disease progression. Front Med (Lausanne). 2021;8(160). DOI:10.3389/fmed.2021.645187
   PubMedGoogle Scholar
• Korbut AI, Taskaeva IS, Bgatova NP, et al. SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db/db mice, a model of type 2 diabetes. Int J Mol Sci. 2020;21(8):2987.
   Web of Science ®Google Scholar
• Xin G, Zhou G, Zhang X, et al. Potential role of upregulated microRNA‑146b and ‑21 in renal fibrosis. Mol Med Rep. 2017;16(3):2863–2867.
   PubMed Web of Science ®Google Scholar
• Gao F, Wang Y, Li S, et al. Inhibition of p38 mitogen-activated protein kinases attenuates renal interstitial fibrosis in a murine unilateral ureteral occlusion model. Life Sci. 2016;167(p):78–84.
   PubMedGoogle Scholar
• Zhang X, Yang Z, Heng Y, et al. MicroRNA‑181 exerts an inhibitory role during renal fibrosis by targeting early growth response factor‑1 and attenuating the expression of profibrotic markers. Mol Med Rep. 2019;19(4):3305–3313.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Riaz F, Chen Q, Lu K, et al. Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway. 2021.
   Google Scholar
• Badal SS, Danesh FR. MicroRNAs and their applications in kidney diseases. Pediatr Nephrol. 2015;30(5):727–740.
   PubMed Web of Science ®Google Scholar
• Zhou H, Hasni SA, Perez P, et al. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. J Am Soc Nephrol. 2013;24(7):1073–1087.
   PubMed Web of Science ®Google Scholar
• Kato M, Natarajan R. Diabetic nephropathy–emerging epigenetic mechanisms. Nat Rev Nephrol. 2014;10(9):517–530.
   PubMed Web of Science ®Google Scholar
• McClelland A, Hagiwara S, Kantharidis P. Where are we in diabetic nephropathy: microRNAs and biomarkers? Curr Opin Nephrol Hypertens. 2014;23(1):80–86.
   PubMed Web of Science ®Google Scholar
• Srivastava SP, Hedayat AF, Kanasaki K, et al. microRNA crosstalk influences epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal transitions in the kidney. Front Pharmacol. 2019;10(904). DOI:10.3389/fphar.2019.00904.
   Google Scholar
• Yu J, Yu C, Feng B, et al. Intrarenal microRNA signature related to the fibrosis process in chronic kidney disease: identification and functional validation of key miRNAs. BMC Nephrol. 2019;20(1):336.
   PubMed Web of Science ®Google Scholar
• Srivastava SP, Shi S, Kanasaki M, et al. Effect of antifibrotic microRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related kidney fibrosis. Sci Rep. 2016;6(1):1–12.
   PubMedGoogle Scholar
• Wong JS, Meliambro K, Ray J, et al. Hippo signaling in the kidney: the good and the bad. Am J Physiol Renal Physiol. 2016;311(2):F241–8.
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73–79.
   PubMed Web of Science ®Google Scholar
• Lai ZC, Wei X, Shimizu T, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 2005;120(5):675–685.
   PubMed Web of Science ®Google Scholar
• Hergovich A. Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci. 2013;3(1):32.
   PubMed Web of Science ®Google Scholar
• Xu J, Li P-X, Wu J, et al. Involvement of the Hippo pathway in regeneration and fibrogenesis after ischaemic acute kidney injury: YAP is the key effector. Clin Sci (London, England: 1979). 2016;130(5):349–363.
   PubMed Web of Science ®Google Scholar
• Guo C, Liang C, Yang J, et al. LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma. Oncol Rep. 2019;41(5):2753–2761.
   PubMed Web of Science ®Google Scholar
• Kim E, Kang JG, Kang MJ, et al. O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proc National Acad Sci USA. 2020;117(25):14259–14269.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yi J, Zhang K, et al. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):161.
   PubMedGoogle Scholar
• Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13(8):877–883.
   PubMed Web of Science ®Google Scholar
• Liu Y, Su -Y-Y, Yang Q, et al. Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis. Stem Cell Res Ther. 2021;12(1):333.
   PubMed Web of Science ®Google Scholar
• Kim CL, Choi SH, Mo JS. Role of the Hippo pathway in fibrosis and cancer. Cells. 2019;8(5):468.
   Web of Science ®Google Scholar
• Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24(9):1488–1501.
   PubMed Web of Science ®Google Scholar
• Sun M, Zhou W, Yao F, et al. MicroRNA-302b mitigates renal fibrosis via inhibiting TGF-β/Smad pathway activation. Braz J Med Biol Res. 2021;54(3):e9206.
   PubMed Web of Science ®Google Scholar
• Padhi BK, Singh M, Huang N, et al. A PCR-based approach to assess genomic DNA contamination in RNA: application to rat RNA samples. Anal Biochem. 2016;494:49–51.
   PubMed Web of Science ®Google Scholar
• Li Y, Xia M, Peng L, et al. Downregulation of miR‑214-3p attenuates mesangial hypercellularity by targeting PTEN‑mediated JNK/c-Jun signaling in IgA nephropathy. Int J Biol Sci. 2021;17(13):3343–3355.
   PubMed Web of Science ®Google Scholar
• Li Q, Yue W, Li M, et al. Downregulating ong non-coding RNAs CTBP1-AS2 inhibits colorectal cancer development by modulating the miR-93-5p/TGF-β/SMAD2/3 pathway. Front Oncol. 2021;11:626620.
   PubMed Web of Science ®Google Scholar
• Li S, Wang Y, Chen L, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berlin, Germany). 2019;97(6):777–791.
   PubMed Web of Science ®Google Scholar
• Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–689.
   PubMed Web of Science ®Google Scholar
• Yu J, Valerius MT, Duah M, et al. Identification of molecular compartments and genetic circuitry in the developing mammalian kidney. Development. 2012;139(10):1863–1873.
   PubMed Web of Science ®Google Scholar
• Fierro-Fernández M, Miguel V, Márquez-Expósito L, et al. MiR-9-5p protects from kidney fibrosis by metabolic reprogramming. Faseb J. 2020;34(1):410–431.
   PubMed Web of Science ®Google Scholar
• Trionfini P, Benigni A, Remuzzi GJNRN. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2015;11(1):23.
   PubMed Web of Science ®Google Scholar
• Yu J, Yu C, Feng B, et al. Intrarenal microRNA signature related to the fibrosis process in chronic kidney disease: identification and functional validation of key miRNAs. BMC Nephrology. 2019;20(1):1–13.
   Google Scholar
• Higgins SP, Tang Y, Higgins CE, et al. TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal. 2018;43:1–10.
   PubMed Web of Science ®Google Scholar
• Szeto SG, Narimatsu M, Lu M, et al. YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis.  Journal of the American Society of Nephrology . 2016;27(10):3117–3128.
   Google Scholar
• Hallan SI, Øvrehus MA, Romundstad S, et al. Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway. Kidney Int. 2016;90(3):665–673.
   PubMed Web of Science ®Google Scholar
• Wühl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol. 2008;23(5):705–716.
   PubMed Web of Science ®Google Scholar
• Yang HC, Fogo AB. Mechanisms of disease reversal in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014;21(5):442–7.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Tuttle KR. Novel therapies for diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(2):121–133.
   PubMed Web of Science ®Google Scholar
• Falke LL, van Vuuren SH, Kazazi-Hyseni F, et al. Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres. Biomaterials. 2015;42:151–160.
   PubMed Web of Science ®Google Scholar
• Kok HM, Falke LL, Goldschmeding R, et al. Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. Nat Rev Nephrol. 2014;10(12):700–711.
   PubMed Web of Science ®Google Scholar
• Yu J, Mao S, Zhang Y, et al. MnTBAP therapy attenuates renal fibrosis in mice with 5/6 nephrectomy. Oxid Med Cell Longev. 2016;2016:7496930.
   PubMed Web of Science ®Google Scholar
• Fan Y, Chen H, Huang Z, et al. Emerging role of miRNAs in renal fibrosis. RNA Biol. 2020;17(1):1–12.
   PubMed Web of Science ®Google Scholar
• Tang J, Yao D, Yan H, et al. The role of microRNAs in the pathogenesis of diabetic nephropathy. Int J Endocrinol. 2019;2019:8719060.
   PubMed Web of Science ®Google Scholar
• Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2015;11(1):23–33.
   PubMed Web of Science ®Google Scholar
• Gomez IG, Nakagawa N, Duffield JS. MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis. Am J Physiol Renal Physiol. 2016;310(10):F931–44.
   PubMed Web of Science ®Google Scholar
• Lv W, Fan F, Wang Y, et al. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics. 2018;50(1):20–34.
   PubMed Web of Science ®Google Scholar
• Cao YX, Wang ZQ, Kang JX, et al. miR-424 protects PC-12 cells from OGD-induced injury by negatively regulating MKP-1. Eur Rev Med Pharmacol Sci. 2018;22(5):1426–1436.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhang L, Hao J, et al. Up-regulation of microRNA-93 inhibits TGF-β1-induced EMT and renal fibrogenesis by down-regulation of Orai1. J Pharmacol Sci. 2018;136(4):218–227.
   PubMed Web of Science ®Google Scholar
• Yu FN, Hu ML, Wang XF, et al. Effects of microRNA-370 on mesangial cell proliferation and extracellular matrix accumulation by binding to canopy 1 in a rat model of diabetic nephropathy. J Cell Physiol. 2019;234(5):6898–6907.
   PubMed Web of Science ®Google Scholar
• Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23(2):252–265.
   PubMed Web of Science ®Google Scholar
• Li R, Chung AC, Dong Y, et al. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-β/Smad3-Azin1 pathway. Kidney Int. 2013;84(6):1129–1144.
   PubMed Web of Science ®Google Scholar
• Shen N, Lin H, Wu T, et al. Inhibition of TGF-β1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis. Kidney Int. 2013;84(1):64–77.
   PubMed Web of Science ®Google Scholar
• Müller R-U, Schermer B. Hippo signaling—a central player in cystic kidney disease? Pediatr Nephrol. 2020;35(7):1143–1152.
   PubMed Web of Science ®Google Scholar
• Anorga S, Overstreet JM, Falke LL, et al. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. Faseb J. 2018;32(5):2644–2657.
   PubMed Web of Science ®Google Scholar